183 related articles for article (PubMed ID: 38135346)
1. Scalable generation of functional human iPSC-derived CAR-macrophages that efficiently eradicate CD19-positive leukemia.
Abdin SM; Paasch D; Kloos A; Oliveira MC; Jang MS; Ackermann M; Stamopoulou A; Mroch PJ; Falk CS; von Kaisenberg CS; Schambach A; Heuser M; Moritz T; Hansen G; Morgan M; Lachmann N
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38135346
[TBL] [Abstract][Full Text] [Related]
2. Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions.
Zhang L; Tian L; Dai X; Yu H; Wang J; Lei A; Zhu M; Xu J; Zhao W; Zhu Y; Sun Z; Zhang H; Hu Y; Wang Y; Xu Y; Church GM; Huang H; Weng Q; Zhang J
J Hematol Oncol; 2020 Nov; 13(1):153. PubMed ID: 33176869
[TBL] [Abstract][Full Text] [Related]
3. CD19 chimeric antigen receptor-redirected T cells combined with epidermal growth factor receptor pathway substrate 8 peptide-derived dendritic cell vaccine in leukemia.
Wu M; Zhang L; Zhang H; Ning J; Tu S; He Y; Li Y
Cytotherapy; 2019 Jun; 21(6):659-670. PubMed ID: 31031152
[TBL] [Abstract][Full Text] [Related]
4. A second-generation M1-polarized CAR macrophage with antitumor efficacy.
Lei A; Yu H; Lu S; Lu H; Ding X; Tan T; Zhang H; Zhu M; Tian L; Wang X; Su S; Xue D; Zhang S; Zhao W; Chen Y; Xie W; Zhang L; Zhu Y; Zhao J; Jiang W; Church G; Chan FK; Gao Z; Zhang J
Nat Immunol; 2024 Jan; 25(1):102-116. PubMed ID: 38012418
[TBL] [Abstract][Full Text] [Related]
5. Ex Vivo Generation of CAR Macrophages from Hematopoietic Stem and Progenitor Cells for Use in Cancer Therapy.
Paasch D; Meyer J; Stamopoulou A; Lenz D; Kuehle J; Kloos D; Buchegger T; Holzinger A; Falk CS; Kloth C; von Kaisenberg CS; Abken H; Schambach A; Lachmann N; Morgan M; Moritz T
Cells; 2022 Mar; 11(6):. PubMed ID: 35326445
[TBL] [Abstract][Full Text] [Related]
6. Induced CAR-Macrophages as a Novel Therapeutic Cell Type for Cancer Immune Cell Therapies.
Su S; Lei A; Wang X; Lu H; Wang S; Yang Y; Li N; Zhang Y; Zhang J
Cells; 2022 May; 11(10):. PubMed ID: 35626689
[TBL] [Abstract][Full Text] [Related]
7. Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors.
Sloas C; Gill S; Klichinsky M
Front Immunol; 2021; 12():783305. PubMed ID: 34899748
[TBL] [Abstract][Full Text] [Related]
8. Generation and Functional Characterization of Anti-CD19 Chimeric Antigen Receptor-Natural Killer Cells from Human Induced Pluripotent Stem Cells.
Klaihmon P; Kang X; Issaragrisil S; Luanpitpong S
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445684
[TBL] [Abstract][Full Text] [Related]
9. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells.
Bai Z; Lundh S; Kim D; Woodhouse S; Barrett DM; Myers RM; Grupp SA; Maus MV; June CH; Camara PG; Melenhorst JJ; Fan R
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006631
[TBL] [Abstract][Full Text] [Related]
10.
Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
Front Immunol; 2022; 13():770132. PubMed ID: 35154098
[TBL] [Abstract][Full Text] [Related]
11. Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products.
Sadeqi Nezhad M; Abdollahpour-Alitappeh M; Rezaei B; Yazdanifar M; Seifalian AM
Pharm Res; 2021 Jun; 38(6):931-945. PubMed ID: 34114161
[TBL] [Abstract][Full Text] [Related]
12. Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy.
Tipanee J; Samara-Kuko E; Gevaert T; Chuah MK; VandenDriessche T
Mol Ther; 2022 Oct; 30(10):3155-3175. PubMed ID: 35711141
[TBL] [Abstract][Full Text] [Related]
13. Generation of anti-GD2 CAR macrophages from human pluripotent stem cells for cancer immunotherapies.
Zhang J; Webster S; Duffin B; Bernstein MN; Steill J; Swanson S; Forsberg MH; Bolin J; Brown ME; Majumder A; Capitini CM; Stewart R; Thomson JA; Slukvin II
Stem Cell Reports; 2023 Feb; 18(2):585-596. PubMed ID: 36638788
[TBL] [Abstract][Full Text] [Related]
14. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
[TBL] [Abstract][Full Text] [Related]
15. Successful organoid-mediated generation of iPSC-derived CAR-T cells.
Kaneko S
Cell Stem Cell; 2022 Apr; 29(4):493-495. PubMed ID: 35395182
[TBL] [Abstract][Full Text] [Related]
16. A simple and effective method to purify and activate T cells for successful generation of chimeric antigen receptor T (CAR-T) cells from patients with high monocyte count.
Wang H; Tsao ST; Gu M; Fu C; He F; Li X; Zhang M; Li N; Hu HM
J Transl Med; 2022 Dec; 20(1):608. PubMed ID: 36536403
[TBL] [Abstract][Full Text] [Related]
17. Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor T Cells: The Intersection of Stem Cells and Immunotherapy.
Lahimchi MR; Maroufi F; Maali A
Cell Reprogram; 2023 Oct; 25(5):195-211. PubMed ID: 37782910
[TBL] [Abstract][Full Text] [Related]
18. Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line.
Kang CH; Kim Y; Lee HK; Lee SM; Jeong HG; Choi SU; Park CH
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33271901
[TBL] [Abstract][Full Text] [Related]
19. 3D-organoid culture supports differentiation of human CAR
Wang Z; McWilliams-Koeppen HP; Reza H; Ostberg JR; Chen W; Wang X; Huynh C; Vyas V; Chang WC; Starr R; Wagner JR; Aguilar B; Yang X; Wu X; Wang J; Chen W; Koelker-Wolfe E; Seet CS; Montel-Hagen A; Crooks GM; Forman SJ; Brown CE
Cell Stem Cell; 2022 Apr; 29(4):515-527.e8. PubMed ID: 35278370
[TBL] [Abstract][Full Text] [Related]
20. When CAR Meets Stem Cells.
Lee JM
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
